What is the latest chemotherapy regimen for ovarian cancer

The latest chemotherapy regimen for ovarian cancer. Since ovarian tumors spread very early, surgery cannot remove the lesions in most cases, and the effect and application of radiotherapy are also very limited. Therefore, systemic chemotherapy is an important auxiliary treatment method. For some advanced patients, the tumor can be reduced after chemotherapy, creating favorable conditions for reoperation.

Based on years of clinical validation, the latest chemotherapy regimen for ovarian cancer is:

① It is better to use large doses intermittently or small doses continuously. The former means taking the medicine for about 1 week per course of treatment, with an interval of about 3 to 4 weeks. This can not only achieve an effective anti-tumor effect, but also help the body eliminate toxicity and restore immune function.

② Combination chemotherapy is more effective than single chemotherapy: In modern times, there is a trend towards combination therapy, but it should be noted that combination chemotherapy has more severe toxic reactions.

③ Based on drug sensitivity tests, selecting sensitive chemotherapy drugs can prolong the patient's survival time.

④ Different chemotherapy regimens are formulated according to tissue type. The commonly used chemotherapy regimens for ovarian cancer in recent years are as follows.

Here are two new chemotherapy regimens for ovarian cancer:

(1) Epithelial cancer and sex cord tumors are often used

①PAC regimen: CTX 400 mg was injected intravenously on the first day, ADM 40 mg was injected intravenously on the second day, and DDP 80 mg was injected intraperitoneally on the third day.

②CFP regimen: CTX 400 mg was injected intravenously on the first day, 5FU150 mg was injected intraperitoneally on the second day, and DDP 80 mg was injected intraperitoneally on the third day.

③CP regimen: CXR 200 mg intravenous injection for 5 consecutive days and DDP 40 mg intravenous drip for 5 consecutive days.

④CHFP regimen: 5FU1000mg intravenous drip on the 1st or 8th day, DDP40mg intravenous drip on the 1st day and 8th day; CTX100mg orally twice a day on the 2nd to 7th day and 9th to 16th day.

(2) Germ cell tumors and sarcomas are often used

①VAC regimen: VCR 2 mg intravenous injection on the first day, ACD 300 ug intravenous drip on the second to sixth days, CTX 300 mg intravenous injection on the second to sixth days,

②FAC regimen: 5Fulooomg intravenous drip for 5 consecutive days, ACD300ug intravenous drip for 5 consecutive days, CTX300mg intravenous injection for 5 consecutive days.

③PVB regimen: VLB 20 mg (or VCR 2 mg) intravenously on the first day, BLM 30 mg intramuscularly or intraperitoneally on the second day, DDP 20-30 mg intravenously or intraperitoneally on the first to fifth days.

Each course of treatment for the above schemes is generally 3-4 weeks apart, and the specific situation should be determined according to the patient's physical condition, degree of reaction, blood picture, liver and kidney function, etc. The medication should be used for at least 4 to 6 courses. For patients with advanced or insensitive tumors, the course of treatment should be more, generally 8 to 10 courses in the first year, and reduced to 3 to 4 courses in the second year.

The above is the latest chemotherapy plan for ovarian cancer introduced to you by experts. I hope it will be helpful to you. In addition, patients are reminded that patients with mid-to-late stage ovarian cancer who are not suitable for surgery generally use a combination of radiotherapy and biological therapy.